Connect with us

Life Sciences

The future of canine stem cell therapy: unprecedented, painless, and feeder-free

Osaka, Japan – Dog owners may need to learn to appreciate their best friend’s urine. Scientists at Osaka Metropolitan University have devised an efficient,…

Published

on

This article was originally published by BioEngineering

Osaka, Japan – Dog owners may need to learn to appreciate their best friend’s urine. Scientists at Osaka Metropolitan University have devised an efficient, non-invasive, and pain-free method to reprogram canine stem cells from urine samples, bringing furry companions one step closer to veterinary regenerative treatment.

Generating canine induced pluripotent stem cells (iPSCs) without using feeder cells

Credit: Shingo Hatoya, Osaka Metropolitan University

Osaka, Japan – Dog owners may need to learn to appreciate their best friend’s urine. Scientists at Osaka Metropolitan University have devised an efficient, non-invasive, and pain-free method to reprogram canine stem cells from urine samples, bringing furry companions one step closer to veterinary regenerative treatment.

Induced pluripotent stem cells (iPSCs) have been widely employed in studies on human generative medicine.  With the growing importance of advanced medical care for dogs and cats, there is an expectation that new therapies utilizing iPSCs will be developed for these companion animals, just as they have been for humans. Unfortunately, canine somatic cells exhibit lower reprogramming efficiency compared to those of humans, limiting the types of canine cells available for generating iPSCs. IPSC induction often involves using feeder cells from a different species. However, considering the associated risks, minimizing xenogeneic components is often advisable, signifying the need to improve the efficiency of reprogramming various types of canine cells in dogs without using feeder cells.

A research team led by Professor Shingo Hatoya and Dr. Masaya Tsukamoto from the Graduate School of Veterinary Science at Osaka Metropolitan University has identified six reprogramming genes that can boost canine iPSC generation by about 120 times compared to conventional methods using fibroblasts. The iPSCs were created from urine-derived cells using a non-invasive, straightforward, and painless method. Additionally, the researchers succeeded in generating canine iPSCs without feeder cells, a feat that had been impossible until now. The team aims to disseminate their findings in the global research community, contributing to advances in regenerative medicine and genetic disease research in veterinary medicine.

“As a veterinarian, I have examined and treated many animals,” explained Professor Hatoya. “However, there are still many diseases that either cannot be cured or have not been fully understood. In the future, I am committed to continue my research on differentiating canine iPSCs into various types of cells and applying them to treat sick dogs, hopefully bringing joy to many animals and their owners.”

Their findings are set for publication in Stem Cell Reports on December 21, 2023.

###

About OMU 

Osaka Metropolitan University is the third largest public university in Japan, formed by a merger between Osaka City University and Osaka Prefecture University in 2022. OMU upholds “Convergence of Knowledge” through 11 undergraduate schools, a college, and 15 graduate schools. For more research news, visit https://www.omu.ac.jp/en/ or follow us on Twitter: @OsakaMetUniv_en, or Facebook. 



cell therapy
stem cells

Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending